于基石药业而言,又一跨界里程碑出现了。7月3日,基石药业披露了两款自主研发的针对自身免疫/炎症性疾病的双特异性抗体药物——CS2013(靶向B细胞激活因子[BAFF]/增殖诱导配体[APRIL])和CS2015(靶向OX40配体[OX40L]/胸腺基质淋巴细胞生成素[TSLP])。这两款分子的首次亮相,也标志着基石药业正式叩开了自免与炎症性疾病领域的大门。消息一出,市场很快就给出了积极反馈——基石...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.